Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design
2.2. Statistical Plan and Data Management
3. Results
4. Discussion
Author Contributions
Funding
Conflicts of Interest
References
- Remuzzi, A.; Remuzzi, G. COVID-19 and Italy: What next? Lancet 2020, 395, 1225–1228. [Google Scholar] [CrossRef]
- Liang, W.; Guan, W.; Chen, R.; Wang, W.; Li, J.; Xu, K.; Li, C.; Ai, Q.; Lu, W.; Liang, H.; et al. Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol. 2020, 21, 335–337. [Google Scholar] [CrossRef]
- Lodigiani, C.; Iapichino, G.; Carenzo, L.; Cecconi, M.; Ferrazzi, P.; Sebastian, T.; Kucher, N.; Studt, J.-D.; Sacco, C.; Alexia, B.; et al. Humanitas COVID-19 Task Force Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb. Res. 2020, 191, 9–14. [Google Scholar] [CrossRef] [PubMed]
- Grasselli, G.; Pesenti, A.; Cecconi, M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response. JAMA 2020. [Google Scholar] [CrossRef] [PubMed]
- Francone, M.; Iafrate, F.; Masci, G.M.; Coco, S.; Cilia, F.; Manganaro, L.; Panebianco, V.; Andreoli, C.; Colaiacomo, M.C.; Zingaropoli, M.A.; et al. Chest CT score in COVID-19 patients: Correlation with disease severity and short-term prognosis. Eur. Radiol. 2020. [Google Scholar] [CrossRef] [PubMed]
- Mei, H.; Dong, X.; Wang, Y.; Tang, L.; Hu, Y. Managing patients with cancer during the COVID-19 pandemic: Frontline experience from Wuhan. Lancet Oncol. 2020, 21, 634–636. [Google Scholar] [CrossRef]
- Zhang, L.; Zhu, F.; Xie, L.; Wang, C.; Wang, J.; Chen, R.; Jia, P.; Guan, H.Q.; Peng, L.; Chen, Y.; et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann. Oncol. 2020, 31, 894–901. [Google Scholar] [CrossRef] [PubMed]
- Richardson, S.; Hirsch, J.S.; Narasimhan, M.; Crawford, J.M.; McGinn, T.; Davidson, K.W.; The Northwell COVID-19 Research Consortium; Barnaby, D.P.; Becker, L.B.; Chelico, J.D.; et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area. JAMA 2020. [Google Scholar] [CrossRef] [PubMed]
- Yu, J.; Ouyang, W.; Chua, M.L.K.; Xie, C. SARS-CoV-2 Transmission in Patients with Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020. [Google Scholar] [CrossRef] [PubMed]
- Ofori-Asenso, R.; Ogundipe, O.; Agyeman, A.A.; Chin, K.L.; Mazidi, M.; Ademi, Z.; De Bruin, M.L.; Liew, D. Cancer is associated with severe disease in COVID-19 patients: A systematic review and meta-analysis. Ecancer 2020, 14, 1047. [Google Scholar] [CrossRef] [PubMed]
- Grasselli, G.; Zangrillo, A.; Zanella, A.; Antonelli, M.; Cabrini, L.; Castelli, A.; Cereda, D.; Coluccello, A.; Foti, G.; Fumagalli, R.; et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020. [Google Scholar] [CrossRef] [PubMed]
- COVID-19 and Cancer|ESMO. Available online: https://www.esmo.org/covid-19-and-cancer (accessed on 8 April 2020).
- ASCO Statement on Novel Coronavirus (COVID-19)|ASCO Annual Meeting. Available online: https://meetings.asco.org/am/asco-statement-novel-coronavirus-covid-19 (accessed on 8 April 2020).
- Lee, L.Y.W.; Cazier, J.B.; Starkey, T.; Turnbull, C.D.; UK Coronavirus Cancer Monitoring Project Team; Kerr, R.; Middleton, G. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: A prospective cohort study. Lancet 2020, 395, 1919–1926. [Google Scholar] [CrossRef]
- Yang, K.; Sheng, Y.; Huang, C.; Jin, Y.; Xiong, N.; Jiang, K.; Lu, H.; Liu, J.; Yang, J.; Dong, Y.; et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: A multicentre, retrospective, cohort study. Lancet Oncol. 2020, 21, 904–913. [Google Scholar] [CrossRef]
- Watson, J.; Whiting, P.F.; Brush, J.E. Interpreting a covid-19 test result. BMJ 2020, 369, m1808. [Google Scholar] [CrossRef] [PubMed]
Chemo | Immuno | Targeted | Chemo-Immuno | Chemo-Targeted | Hormonal-Targeted | Other | Total (%) | |
---|---|---|---|---|---|---|---|---|
Inpatients | 405 | 129 | 128 | 19 | 98 | 0 | 35 | 814 |
SARS-CoV-2 | 5 | 2 | 0 | 1 | 1 | 0 | 1 | 10 (1.2%) |
Outpatients | 194 | 0 | 182 | 0 | 0 | 77 | 0 | 453 |
SARS-CoV-2 | 1 | 0 | 4 | 0 | 0 | 2 | 0 | 7 (1.5%) |
Patient | Sex | Age | Cancer Diagnosis | BMI | Smoking | Comorbidities | Stage of Disease | Active Treatment | G-CSF |
---|---|---|---|---|---|---|---|---|---|
1 | M | 77 | Prostate cancer | 29.7 | Yes | HT, DLD | Metastatic | Chemo-Immuno | Yes |
2 | F | 65 | Breast cancer | 25.3 | No | HT, DLD | Metastatic | Hormonal-Targeted | No |
3 | M | 71 | Laryngeal small cell cancer | 27.6 | Yes | HT, DLD, CAD, DM | Locally advanced | Chemo | Yes |
4 | M | 55 | CNS | 23.0 | No | - | Local recurrence | Chemo | No |
5 | F | 58 | Renal clear cell cancer | 21.8 | No | HT | Metastatic | Targeted | No |
6 | M | 43 | CNS | 27.4 | No | DLD | Local recurrence | Targeted | No |
7 | F | 66 | Mesothelioma | 23.3 | No | HT | Metastatic | Chemo | No |
8 | F | 79 | Renal clear cell cancer | 20.7 | Ex | HT, RA | Metastatic | Immuno | No |
9 | M | 70 | Pancreatic cancer | 20.0 | No | CAD, DM, CVA | Adjuvant | Chemo | No |
10 | M | 60 | Prostate cancer | 27.7 | No | - | Metastatic | Immuno | No |
11 | F | 45 | Melanoma | 33.6 | No | - | Adjuvant | Targeted | No |
12 | F | 79 | Breast cancer | 21.4 | No | DLD | Adjuvant | Chemo-Targeted | No |
13 | F | 71 | Breast cancer | 32.4 | Ex | HT, COPD, RA | Metastatic | Hormonal-Targeted | No |
14 | F | 60 | Lung cancer | 22.3 | Ex | - | Metastatic | Immuno-Targeted | No |
15 | M | 75 | Lung cancer | 35.3 | Yes | HT, CAD, DLD, COPD | Metastatic | Chemo | No |
16 | F | 68 | Lung cancer | 24.1 | No | HT, PE | Metastatic | Targeted | No |
17 | M | 47 | Gastric cancer | 25.1 | No | DLD | Metastatic | Chemo | No |
Patient | Time to Diagnosis (Days) | Symptoms | IL-6 (pg/mL) * | CT Findings (SS) | Therapies | Management | In-Hospital Stay (Days) | Time to Negative Swab (Days) | Outcome |
---|---|---|---|---|---|---|---|---|---|
1 | 6 | Abdominal pain | 4 | Unilateral single GGO (1) | HCQ, AV, AB, O2 | Hospitalised | 15 | n/a | DOC |
2 | 2 | Fever, cough, SOB | n/a | n/a | HCQ, O2 | Hospitalised | 5 | n/a | DOC |
3 | 1 | Shock | n/a | Diffuse bilateral GGO (9) | - | Hospitalised | 7 | n/a | DOC |
4 | 2 | Fever, cough | 5 | Bilateral basal dysventilation (0) | HCQ, AV, AB, O2 | Hospitalised | 29 | n/a | Alive |
5 | 0 | - | 3 | Bilateral GGO, hilar bilateral adenopathies (2) | - | Hospitalised | 3 | 24 | Alive |
6 | 0 | SOB, shock | n/a | n/a | O2 | Hospitalised | 4 | n/a | DOD |
7 | 3 | SOB | n/a | n/a | HCQ, AV, AB, O2 | Hospitalised | 30 | n/a | DOD/DOC |
8 | 4 | Fever | n/a | Unremarkable (0) | HCQ, AV, AB, O2 | Hospitalised | 8 | 19 | Alive |
9 | 1 | Fever | n/a | n/a | HCQ, O2 | Hospitalised | 30 | 30 | Alive |
10 | 8 | Fever, cough | n/a | Unremarkable (0) | HCQ | Isolation | - | 10 | Alive |
11 | 0 | - | n/a | Unilateral GGO (3) | - | Isolation | - | 33 | Alive |
12 | 1 | Fever | n/a | n/a | HCQ, AV, AB, O2 | Hospitalised | 24 | 18 | Alive |
13 | 1 | Fever | n/a | Unremarkable (0) | - | Isolation | - | 41 | Alive |
14 | 1 | Pain | 55 | GGO, pleural effusion (3) | HCQ | Hospitalised | 30 | 14 | Alive |
15 | 1 | Fever, SOB | GGO, hilar bilateral adenopathies (7) | HCQ, AV, O2 | Hospitalised | 58 | 82 | Alive | |
16 | 1 | Fever | Unremarkable (0) | HCQ, AB, O2 | Hospitalised | 8 | 15 | Alive | |
17 | 1 | Abdominal pain | 2 | Bilateral GGO (2) | HCQ, AV, AB, O2 | Hospitalised | 8 | 42 | Alive |
Patient | Sex | Age (Years) | Diagnosis | BMI | Smoking | IL-6 (pg/mL) * | CT Findings (SS) | Comorbidities | Stage of Disease | Management | Outcome |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | M | 89 | Bladder cancer | 29.4 | Ex | n/a | Bilateral ground-glass consolidation, adenopathies, pleural effusion (12) | CAD, COPD | Localised | Hospitalised | DOC |
2 | M | 63 | Cholangiocarcinoma | 46.9 | Ex | 1 | Bilateral diffuse ground-glass consolidation (7) | DM, HT, COPD, CAD | Locally advanced | Hospitalised | DOD |
3 | F | 70 | Cholangiocarcinoma | 29.4 | No | 7 | n/a | - | Locally advanced | Hospitalised | Alive |
4 | F | 76 | Cholangiocarcinoma | 18.5 | No | n/a | Left lobe consolidation, pleural effusion (5) | - | Locally advanced | Hospitalised | DOD |
5 | M | 66 | Lung cancer | 22.6 | Ex | n/a | Bilateral ground-glass consolidation, pleural effusion (6) | CAD | Metastatic | Hospitalised | DOC/DOD |
6 | F | 79 | Pancreatic cancer | 27.6 | Yes | 2 | Bilateral ground-glass consolidation, adenopathy, PE (20) | DM | Metastatic | Hospitalised | DOD |
7 | M | 68 | Oesophageal cancer | 18.8 | Ex | 4 | Bilateral ground-glass consolidation (2) | DM, HT | Locally advanced | Hospitalised | Alive |
8 | M | 67 | Lung cancer | 23.9 | Ex | 7 | n/a | - | Metastatic | Hospitalised | DOC/ DOD |
9 | F | 69 | Lung cancer | 25.4 | No | n/a | Bilateral ground-glass consolidation, adenopathy, pleural effusion (14) | - | Metastatic | Hospitalised | DOC/ DOD |
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bertuzzi, A.F.; Marrari, A.; Gennaro, N.; Cariboni, U.; Ciccarelli, M.; Giordano, L.; Quagliuolo, V.L.; Santoro, A. Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy. Cancers 2020, 12, 2352. https://doi.org/10.3390/cancers12092352
Bertuzzi AF, Marrari A, Gennaro N, Cariboni U, Ciccarelli M, Giordano L, Quagliuolo VL, Santoro A. Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy. Cancers. 2020; 12(9):2352. https://doi.org/10.3390/cancers12092352
Chicago/Turabian StyleBertuzzi, Alexia Francesca, Andrea Marrari, Nicolò Gennaro, Umberto Cariboni, Michele Ciccarelli, Laura Giordano, Vittorio Lorenzo Quagliuolo, and Armando Santoro. 2020. "Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy" Cancers 12, no. 9: 2352. https://doi.org/10.3390/cancers12092352
APA StyleBertuzzi, A. F., Marrari, A., Gennaro, N., Cariboni, U., Ciccarelli, M., Giordano, L., Quagliuolo, V. L., & Santoro, A. (2020). Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy. Cancers, 12(9), 2352. https://doi.org/10.3390/cancers12092352